The National Cancer Institute (NCI) awarded a $148,568 Project Grant (CFDA 93.398 - Cancer Research Manpower) to The Leland Stanford Junior University on December 17, 2024. The grant, titled "INTEGRATING HIGHLY MULTIPLEXED IMMUNOFLUORESCENCE WITH LABEL-FREE 2D HYPERSPECTRAL CHEMICAL IMAGING TO INTERROGATE THE COLORECTAL CANCER TUMOR-INVASIVE FRONT," supports research aimed at understanding colorectal cancer biology through the integration of advanced imaging techniques. The project...
This $131,220 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support cancer vaccine research under the Cancer Research Manpower federal grant program (CFDA 93.398). The grant recipient, Stanford University, will develop a new approach to cancer vaccination that directly reprograms cancer cells into antigen presenting cells (APCs) through mRNA-enabled cell reprogramming. Researchers aim to overcome barriers to current vaccination...
The National Cancer Institute (NCI) awarded a $432,837 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to The Leland Stanford Junior University. The grant, with a start date of July 1, 2024 and an end date of December 31, 2024, will fund research to: (1) define the most therapeutically relevant CAR T cell subsets in patients with large B cell lymphoma (LBCL), and (2) overcome an immune suppression mechanism of resistance to CAR T cell therapy for LBCL. The...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to The Leland Stanford Junior University will support research to elucidate how microbial microproteins modulate macrophage function, a critical coordinator of tumor immune response. The $640,522 award, effective May 1, 2025 through April 30, 2030, will fund three key research aims: 1) determining the molecular mechanisms by which two identified microbial proteins modulate macrophage polarization,...
The National Cancer Institute (NCI) awarded a $293,369 Project Grant (CFDA 93.398 - Cancer Research Manpower) to Duke University to investigate the mechanisms by which residual tumor cells evade the immune system after oncogene-targeted cancer therapies. The research aims to uncover potential targets and approaches to enhance the immune-mediated clearance of these residual cells, which often serve as the reservoir for treatment resistance and relapse. Using mouse melanoma models and human cancer...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $330,942 to Stanford University over a 5-year period from September 2024 to August 2029. The purpose of the grant is to develop scalable screening methodologies to rapidly assess the performance of approved and proposed cellular immunotherapy constructs across large numbers of cancer patients. The research will also investigate the intrinsic variability of patient T cells...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $179,988 to The Leland Stanford Junior University to conduct research aimed at understanding how the gut microbiome can be modulated to enhance immune responses against cancer. The central hypothesis is that discrepancies in findings between studies on the microbiome's impact on immunotherapy are explained by shared functional basis within distinct microbial taxa. The research...
This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $207,900.00 to The Leland Stanford Junior University to develop a three-cell synthetic immunotherapy system. The research aims to engineer chimeric antigen receptor (CAR) expressing T cells, natural killer (NK) cells, and macrophages that can function...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program provides $626,513.72 to The Leland Stanford Junior University for a 3-year period starting January 1, 2025. The research aims to: (1) define the most therapeutically relevant CAR T cell subsets in patients with large B cell lymphoma (LBCL), and (2) overcome an immune suppression mechanism of resistance to CAR T cell therapy for LBCL. The work will involve single-cell sequencing,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $552,874 in funding to The Regents of the University of California, San Francisco (UCSF) for a 5-year period from Aug 1, 2024 to Jul 31, 2029. The grant will support research to precisely dissect the cellular and molecular pathways by which the A20 protein regulates anti-tumor immunity. The goal is to gain a better understanding of how tumors persist and grow within tissues by...
This Project Grant award in the amount of $509,448.00 was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The funding supports research aimed at understanding the role of antigen-presenting cells (APCs) in modulating tumor-specific immune tolerance, which can lead to metastatic progression. The grantee, The Leland Stanford Junior University, will use advanced techniques like high-dimensional imaging, single-cell RNA sequencing, and in vivo cell depletion models to identify the key APC population responsible for inducing tumor-specific regulatory T cells. Additionally, the researchers will develop and test immunostimulatory antibody conjugates that can reprogram APCs to overcome this tumor-induced immune tolerance, with the goal of improving treatments for metastatic cancer. The award period runs from August 22, 2024 to February 28, 2027.